Skip to main content
main-content
Top

03-30-2017 | Insulin glargine | Article

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Journal: Diabetes Therapy

Authors: Liza L. Ilag, Timothy M. Costigan, Mark A. Deeg, Robyn K. Pollom, Curtis L. Chang, Robert J. Konrad, Melvin J. Prince

Publisher: Springer Healthcare

share
SHARE

Abstract

Introduction

We compared insulin antibody response (IAR) profiles in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) who received LY2963016 insulin glargine (LY IGlar) or Lantus® insulin glargine (IGlar) and evaluated the potential relationship between higher IARs and clinical and safety outcomes with a focus on patients who exhibited antibody responses in the upper quartile.

Methods

Data from ELEMENT-1 (52-week open-label in T1D) and ELEMENT-2 (24-week, double-blind study in T2D) were analyzed. Maximum postbaseline IAR levels and proportions of patients in the upper quartile of maximum antibody percent binding (UQMAPB; patients with maximum postbaseline percent binding in the highest 25% of maximum values observed) were compared for differential treatment effects on clinical efficacy outcomes and incidence of adverse events. Continuous outcomes were analyzed by analysis of covariance. Categorical data were analyzed by the Cochran–Mantel–Haenszel or Breslow–Day test.

Results

In both studies (N = 532 evaluable patients with T1D; N = 730 with T2D), no statistically significant differences between LY IGlar and IGlar were observed for maximum antibody percent binding (MAPB) levels or for proportions of patients in the respective UQMAPB. No statistically significant differential treatment effects were observed in the relationship between MAPB and clinical efficacy and safety outcomes.

Conclusions

Maximum postbaseline IAR levels and the proportion of patients with high IAR levels were similar for LY IGlar and IGlar. High antibody levels did not affect clinical outcomes. These results add further evidence supporting similar IARs of LY IGlar and IGlar.

Funding

Eli Lilly and Company and Boehringer-Ingelheim.
Literature
1.
Eli Lilly and Company. European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe (news release). Indianapolis, IN: Eli Lilly and Company, Boehringer Ingelheim; September 10, 2014. http://​lilly.​mediaroom.​com/​index.​php?​s=​9042&​item=​137348. Accessed 18 May 2015.
2.
Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2014. http://​www.​pmda.​go.​jp/​files/​000206818.​pdf. Accessed 10 Dec 2015.
3.
US Food and Drug Administration. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes (news release). December 16, 2015. http://​www.​fda.​gov/​newsevents/​newsroom/​pressannouncemen​ts/​ucm477734.​htm. Accessed 02 Nov 2016.
4.
Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38:2226–33. doi: 10.​2337/​dc14-2623. CrossRefPubMed
5.
Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17:726–33. doi: 10.​1111/​dom.​12496. CrossRefPubMed
6.
Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus ®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17:734–41. doi: 10.​1111/​dom.​12482. CrossRefPubMed
7.
Ilag LL, Deeg MA, Costigan T, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus ® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:159–68. doi: 10.​1111/​dom.​12584. CrossRefPubMedPubMedCentral
8.
Dolinar RO, Edelman S, Heinemann L, et al. Impact of biosimilar insulins on clinical practice: meeting report. J Diabetes Sci Technol. 2014;8:179–85. doi: 10.​1177/​1932296813518267​. CrossRefPubMedPubMedCentral
9.
Polimeni G, Trifirò G, Ingrasciotta Y, Caputi AP. The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetol. 2015;52:423–31. doi: 10.​1007/​s00592-015-0771-7. CrossRefPubMed
10.
Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations—a cause for concern? Diabetes Technol Ther. 2012;14:989–96. doi: 10.​1089/​dia.​2012.​0105. CrossRefPubMedPubMedCentral
11.
Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of clinical immunogenicity of therapeutic proteins and peptides–harmonized terminology and tactical recommendations. AAPS J. 2014;16:658–73. doi: 10.​1208/​s12248-014-9599-2. CrossRefPubMedPubMedCentral
12.
World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–6. doi: 10.​1001/​jama.​1997.​03540350075038. CrossRef
13.
American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–9. doi: 10.​2337/​diacare.​28.​5.​1245. CrossRef
14.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). 2012. Guideline on the clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2012/​06/​WC500129256.​pdf. Accessed 09 March 2016.
15.
European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). 2002. Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2009/​09/​WC500003262.​pdf. Accessed 08 March 2016.
16.
Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639–43. doi: 10.​2337/​diacare.​23.​5.​639. CrossRefPubMed
17.
Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130–6. doi: 10.​2337/​diacare.​23.​8.​1130. CrossRefPubMed
18.
Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464–71. doi: 10.​2337/​dc12-1205. CrossRefPubMedPubMedCentral
19.
Vlajnic A, Traylor L, Frimpter J, Khatami H, Schellekens H. The immunogenicity of originator insulin glargine: incidence and absence of clinical sequelae. Diabetologia. 2014;57(Suppl1):S397.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions